Seres Therapeutics, Inc.
MCRB evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $55.8M
What it means
What to watch
Prepared research question
What matters most for MCRB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MCRB
Seres Therapeutics is a clinical-stage biotechnology company developing live biotherapeutic products for oncology and inflammatory diseases, with a lead program in early-stage development and a limited cash runway extending into early 2027.
Key risk: Limited cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$55.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Seres Therapeutics, Inc..
Seres Therapeutics is a clinical-stage biotechnology company developing live biotherapeutic products for oncology and inflammatory diseases, with a lead program in early-stage development and a limited cash runway extending into early 2027.
- Seres is a clinical-stage company focused on live biotherapeutic products (LBPs) for oncology and inflammatory/immune diseases [sec · filed 2026-08-13].
- The company sold its first FDA-approved microbiome therapeutic, VOWST, to Nestlé Health Science in September 2024 [sec · filed 2026-08-13].
- Cash and equivalents were $15.6M as of 2026-06-30 [sec].
- Net loss from operations was $42.2 million for the six months ended June 30, 2026, with an accumulated deficit of $987.7 million as of that date [sec_mda · as of 2026-08-05].
- A June 2026 transaction with Nestlé provided $25 million and extended projected cash runway into Q1 2027 [news · published 2026-06-05].
What works
- Seres has established field-leading capabilities and platforms powered by best-in-field human data sets to address diseases at the mucosal barrier-immune interface [sec · filed 2026-08-13].
- The company received a non-dilutive CARB-X award of up to $3.6 million in 2025 to support development of an oral liquid formulation (SER-428) for ICU patients [sec_mda · as of 2026-08-05].
- FDA has endorsed the primary endpoint and interim analysis strategy for SER-155, and indicated openness to an expedited path to Phase 3 if interim analysis shows overwhelming efficacy [sec · filed 2026-04-27].
What to weigh
- Seres has incurred significant operating losses since inception, with a net loss of $42.2 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-05].
- As of June 30, 2026, the company had an accumulated deficit of $987.7 million [sec_mda · as of 2026-08-05].
- The company's product candidates are in early-stage clinical or preclinical development, and profitability depends on successful development and commercialization [sec_mda · as of 2026-05-05].
- Cash runway extends only into Q1 2027, requiring additional funding to advance pipeline programs [news · published 2026-06-05].
From the filings
Quoted directly from source documents.
Seres sold VOWST to Nestlé Health Science in September 2024.
“VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A. and with certain of its affiliates in September 2024.”
SEC filings · August 13, 2026
Net loss from operations was $42.2 million for the six months ended June 30, 2026.
“Our net loss from operations was $42.2 million for the six months ended June 30, 2026.”
SEC MD&A · August 5, 2026
Accumulated deficit as of June 30, 2026 was $987.7 million.
“As of June 30, 2026, we had an accumulated deficit of $987.7 million.”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash runway extends only into Q1 2027, requiring additional funding to continue operations and advance pipeline [news · published 2026-06-05].
- Significant accumulated deficit — Accumulated deficit of $987.7M as of June 30, 2026, with ongoing net losses [sec_mda · as of 2026-08-05].
- Early-stage pipeline — All product candidates are in early-stage clinical or preclinical development; profitability is uncertain [sec_mda · as of 2026-05-05].
- Dependence on FDA feedback — Clinical development path for SER-155 depends on FDA endorsement and interim analysis results [sec · filed 2026-04-27].
What to watch
- Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later in June 2026 [news · published 2026-06-05].
- Progress of IND-enabling studies for SER-603 and evaluation of next-stage development for SER-155 in irEC [sec_mda · as of 2026-08-05].
- Ability to secure additional funding to extend cash runway beyond Q1 2027 [news · published 2026-06-05].
- FDA feedback and potential expedited path to Phase 3 for SER-155 [sec · filed 2026-04-27].
Sources: News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Seres Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Seres Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.94 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 7.4%
- Days to cover
- 10.6
- Shares short
- 540,750
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MCRB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Seres Therapeutics, Inc.?
Seres Therapeutics is a clinical-stage biotechnology company developing live biotherapeutic products for oncology and inflammatory diseases, with a lead program in early-stage development and a limited cash runway extending into early 2027.
Who is the CEO of Seres Therapeutics, Inc.?
Mr. Richard N. Kender B.S., M.B.A. is the chief executive officer of Seres Therapeutics, Inc. (MCRB).
Where is Seres Therapeutics, Inc. headquartered?
Seres Therapeutics, Inc. (MCRB) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Seres Therapeutics, Inc. focus on?
Seres Therapeutics, Inc. develops therapies across Immunology, Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.